SynthesisObesity surgery2026
Intraoperative Esketamine to Reduce Postoperative Pain and Opioid Consumption in Bariatric Surgery: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBariatric surgeries cause severe pain, often requiring opioids that have significant side effects. Esketamine, an NMDA receptor antagonist, is proposed as an opioid-sparing adjunct, but evidence remains unclear in this population.
methodsFollowing PRISMA guidelines, we searched PubMed, Scopus, and Web of Science until July 2025 for RCTs comparing intraoperative esketamine to control in adult bariatric surgery. The primary outcomes were postoperative pain and opioid consumption. Secondary outcomes included patient recovery and other perioperative metrics. We used a random-effects model for pooled analysis.
resultsSix RCTs with 582 patients were included. For the primary outcomes, esketamine showed no statistically significant difference in VAS pain scores (MD = 0.14; 95% CI: -1.23 to 1.51) and a non-significant reduction in rescue analgesic use (RR = 0.53; 95% CI: 0.20 to 1.41). Regarding secondary outcomes, there was a statistically significant but clinically modest improvement in early patient recovery on postoperative day 1 (SMD = 0.44; 95% CI: 0.13 to 0.75). Other metrics like extubation time, length of hospital stay, and PONV showed no significant differences.
conclusionIntraoperative esketamine does not significantly reduce postoperative pain intensity or overall opioid consumption in bariatric surgery. While it offers a statistically significant but clinically modest benefit for early patient recovery, its routine use as a primary opioid-sparing agent is not strongly supported, however the observed suggest that esketamine may hold potential as an adjunctive treatment, though further large-scale, international research is required to fully determine its clinical utility.
Indexed as
Identifiers
42008073What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.